Regorafenib - Bayer Healthcare

Drug Profile

Regorafenib - Bayer Healthcare

Alternative Names: BAY-734506; DAST inhibitor - Bayer; fluoro-sorafenib; Stivarga

Latest Information Update: 09 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; British Columbia Cancer Agency; Memorial Sloan-Kettering Cancer Center; Ono Pharmaceutical; Spanish Cooperative Group for Digestive Tumour Therapy
  • Class Amides; Antineoplastics; Eye disorder therapies; Fluorobenzenes; Phenylurea compounds; Pyridines; Small molecules
  • Mechanism of Action Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; TIE 2 receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastrointestinal stromal tumours; Hepatocellular carcinoma
  • Phase II Adenocarcinoma; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Discontinued Non-small cell lung cancer; Wet age-related macular degeneration

Most Recent Events

  • 25 Jan 2018 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in Japan (PO) (NCT03406871)
  • 13 Dec 2017 Registered for Hepatocellular carcinoma (Second-line therapy or greater) in China (PO)
  • 11 Dec 2017 Bayer completes a phase II trial in Colorectal cancer (Metastatic disease, Second-line therapy or greater, Antiangiogenic-naive) in Brazil (PO) (NCT02465502)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top